Department of Oral Medicine, State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Frontier Innovation Center for Dental Medicine Plus, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Department of Oral Medicine, Stomatological Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China.
J Cutan Pathol. 2024 Feb;51(2):114-118. doi: 10.1111/cup.14547. Epub 2023 Oct 17.
Lichen planus pemphigoides (LPP) is a rare autoimmune subepidermal disease that can occur in patients receiving immune checkpoint inhibitors. Its clinical manifestations are combined with the characteristics of lichen planus with bullous pemphigoid that can occur on either skin or oral mucosa. It should be noted that oral LPP is very rare. Here, we report a novel case of oral LPP induced by an anti-PD-1 agent. The patient presented with typical clinical features in oral mucosa, and the diagnosis was based on histopathology and immunological studies. Given that the patient was receiving an anti-PD-1 agent, topical therapy was chosen, and a nice therapeutic effect was obtained. No significant recurrence was observed after a 2-year follow-up. A good and stable therapeutic effect achieved by rapid and local symptomatic medication suggests that accurate and sensitive diagnosis is necessary.
天疱疮样扁平苔藓(lichen planus pemphigoides,LPP)是一种罕见的自身免疫性表皮下疾病,可发生于接受免疫检查点抑制剂治疗的患者。其临床表现结合了扁平苔藓和大疱性类天疱疮的特征,可发生于皮肤或口腔黏膜。值得注意的是,口腔 LPP 非常罕见。在此,我们报告一例由抗 PD-1 药物引起的口腔 LPP 新病例。患者口腔黏膜表现出典型的临床特征,诊断基于组织病理学和免疫研究。鉴于患者正在接受抗 PD-1 药物治疗,选择了局部治疗,获得了良好的治疗效果。经过 2 年的随访,未见明显复发。通过快速和局部对症药物治疗获得良好且稳定的治疗效果表明,准确和敏感的诊断是必要的。